The oncogenic and growth-suppressive functions of the integrin-linked kinase are distinguished by JNK1 expression in human cancer cells

Cell Cycle

Volumn 9, Issue 10, 2010, Pages 1951-1959

  Durbin, Adam David ^a,b,c   Pasic, Ivan ^b,c   Wong, Dennis K ^a,c   Hannigan, Gregory Edward ^d   Malkin, David ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Growth suppressor; ILK; JNK1; Oncogene; Tumor suppressor

Indexed keywords

BIOLOGICAL MARKER; INTEGRIN LINKED KINASE; NITROBLUE TETRAZOLIUM; STRESS ACTIVATED PROTEIN KINASE;

ADRENAL CORTEX CARCINOMA; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER INHIBITION; CELL STRAIN MCF 7; CELL TRANSFORMATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; HEPATOBLASTOMA; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NEPHROBLASTOMA; NEUROBLASTOMA; ONCOGENE; PANCREAS TUMOR; PROMOTER REGION; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

EID: 77953638719     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.10.11554     Document Type: Article

References (43)

1. Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 2005; 5:5-7.
2. McDonald PC, Fielding AB, Dedhar S. Integrin-linked kinase - essential roles in physiology and cancer biology. J Cell Sci 2008; 121:3121-32.
3. White DE, Cardiff RD, Dedhar S, Muller WJ. Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene 2001; 20:7064-72.
4. Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, et al. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res 2006; 66:393-403.
5. Tan C, Cruet-Hennequart S, Troussard A, Fazli L, Costello P, Sutton K, et al. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 2004; 5:79-90.
6. Yau CY, Wheeler JJ, Sutton KL, Hedley DW. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 2005; 65:1497-504.
7. Koul D, Shen R, Bergh S, Lu Y, de Groot JF, Liu TJ, et al. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther 2005; 4:1681-8.
8. Durbin AD, Hannigan GE, Malkin D. Oncogenic ILK, tumor suppression and all that JNK. Cell Cycle 2009; 8:4060-6.
9. Lorenz K, Grashoff C, Torka R, Sakai T, Langbein L, Bloch W, et al. Integrin-linked kinase is required for epidermal and hair follicle morphogenesis. J Cell Biol 2007; 177:501-13.
10. Gkretsi V, Apte U, Mars WM, Bowen WC, Luo JH, Yang Y, et al. Liver-specific ablation of integrin-linked kinase in mice results in abnormal histology, enhanced cell proliferation, and hepatomegaly. Hepatology 2008; 48:1932-41.
11. Apte U, Gkretsi V, Bowen WC, Mars WM, Luo JH, Donthamsetty S, et al. Enhanced liver regeneration following changes induced by hepatocyte-specific genetic ablation of integrin-linked kinase. Hepatology 2009.
12. Haase M, Gmach CC, Eke I, Hehlgans S, Baretton GB, Cordes N. Expression of integrin-linked kinase is increased in differentiated cells. J Histochem Cytochem 2008; 56:819-29.
13. Miller MG, Naruszewicz I, Kumar AS, Ramlal T, Hannigan GE. Integrin-linked kinase is a positive mediator of L6 myoblast differentiation. Biochem Biophys Res Commun 2003; 310:796-803.
14. Chen P, Shen WZ, Karnik P. Suppression of malignant growth of human breast cancer cells by ectopic expression of integrin-linked kinase. Int J Cancer 2004; 111:881-91.
15. Cordes N. Overexpression of hyperactive integrin-linked kinase leads to increased cellular radiosensitivity. Cancer Res 2004; 64:5683-92.
16. Hess F, Estrugo D, Fischer A, Belka C, Cordes N. Integrin-linked kinase interacts with caspase-9 and -8 in an adhesion-dependent manner for promoting radiation-induced apoptosis in human leukemia cells. Oncogene 2007; 26:1372-84.
17. Durbin AD, Somers GR, Forrester M, Pienkowska M, Hannigan GE, Malkin D. JNK1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma. J Clin Invest 2009; 119:1558-70.
18. McDonald PC, Dedhar S, Keller C. Integrin-linked kinase: both Jekyll and Hyde in rhabdomyosarcoma. J Clin Invest 2009; 119:1452-5.
19. Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, et al. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Res 2009; 11:25.
20. Muranyi AL, Dedhar S, Hogge DE. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells. Exp Hematol 2009; 37:450-60.
21. Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D, et al. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 2001; 276:27462-9.
22. Dos Santos N, Habibi G, Wang M, Law JH, Andrews HA, Wei D, et al. Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK). Translational Oncogenomics 2007; 2:67-79.
23. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996; 15:2760-70. (Pubitemid 26176253)
24. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103:239-52.
25. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3:859-68.
26. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4:131-6.
27. Sabapathy K, Wagner EF. JNK2: a negative regulator of cellular proliferation. Cell Cycle 2004; 3:1520-3. (Pubitemid 40521404)
28. Perdiguero E, Ruiz-Bonilla V, Serrano AL, Munoz-Canoves P. Genetic deficiency of p38alpha reveals its critical role in myoblast cell cycle exit: the p38alpha-JNK connection. Cell Cycle 2007; 6:1298-303. (Pubitemid 47327960)
29. Troussard AA, Costello P, Yoganathan TN, Kumagai S, Roskelley CD, Dedhar S. The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9). Oncogene 2000; 19:5444-52.
30. Quelo I, Gauthier C, Hannigan GE, Dedhar S, St-Arnaud R. Integrin-linked kinase regulates the nuclear entry of the c-Jun coactivator alpha-NAC and its coactivation potency. J Biol Chem 2004; 279:43893-9.
31. Wu C, Keightley SY, Leung-Hagesteijn C, Radeva G, Coppolino M, Goicoechea S, et al. Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity. J Biol Chem 1998; 273:528-36.
32. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244:217-21.
33. de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 2008; 22:449-62.
34. Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A, et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 2009; 16:324-35.
35. Liu J, Costello PC, Pham NA, Pintillie M, Jabali M, Sanghera J, et al. Integrin-linked kinase inhibitor KP-392 demonstrates clinical benefits in an orthotopic human non-small cell lung cancer model. J Thorac Oncol 2006; 1:771-9.
36. Huang Y, Li J, Zhang Y, Wu C. The roles of integrin-linked kinase in the regulation of myogenic differentiation. J Cell Biol 2000; 150:861-72.
37. McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, et al. Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 2008; 68:1618-24.
38. Alami J, Williams BR, Yeger H. Derivation and characterization of a Wilms' tumour cell line, WiT 49. Int J Cancer 2003; 107:365-74.
39. Barenboim-Stapleton L, Yang X, Tsokos M, Wigginton JM, Padilla-Nash H, Ried T, et al. Pediatric pancreatoblastoma: histopathologic and cytogenetic characterization of tumor and derived cell line. Cancer Genet Cytogenet 2005; 157:109-17.
40. Pasic I, Shlien A, Durbin AD, Stavropoulos DJ, Baskin B, Ray PN, et al. Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. Cancer Res 2010; 70:160-71.
41. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3:1101-8.
42. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, et al. NCBI GEO: mining tens of millions of expression profiles - database and tools update. Nucleic Acids Res 2007; 35:760-5.
43. Greenberg JA, Somme S, Russnes HE, Durbin AD, Malkin D. The estrogen receptor pathway in rhabdomyosarcoma: a role for estrogen receptor-beta in proliferation and response to the antiestrogen 4′OH-tamoxifen. Cancer Res 2008; 68:3476-85.